Stryker (NYSE:SYK – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.450-13.700 for the period, compared to the consensus estimate of 13.510. The company issued revenue guidance of -.
Analyst Ratings Changes
A number of research firms have recently commented on SYK. Canaccord Genuity Group upped their target price on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $425.00 target price on shares of Stryker in a research note on Tuesday, January 7th. Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, Citigroup boosted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.
Read Our Latest Stock Analysis on SYK
Stryker Stock Performance
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Sell-side analysts anticipate that Stryker will post 12.06 earnings per share for the current year.
Stryker Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s dividend payout ratio (DPR) is 36.01%.
Insiders Place Their Bets
In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
- Five stocks we like better than Stryker
- What Are the FAANG Stocks and Are They Good Investments?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Investing In Automotive Stocks
- What Does the Future Hold for Eli Lilly?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.